Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ukrainian man arrested in Germany on suspicion of spying for Russia - 2Jamie Dimon warns Iran war could drive inflation, interest rates higher
- 3Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- 4Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- 5Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- If everyone on Earth sat in the ocean at once, how much would sea level rise?
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- Which Exhibition hall Do You Suggest? Vote
- A top Marine shares his secrets to keeping fit at 50
- Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- Flu surges across U.S. as doctor visits reach highest level since 1997
- Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- Dental Embed Developments: Upsetting Current Dentistry
- Tesla plans to expand production at German car plant
